We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
By
Julia Sacher, PET Centre Centre for Addiction and Mental Health Toronto, ON, Canada,
Gwenn S. Smith, Department of Psychiatry and Behavioral Sciences The Johns Hopkins University School of Medicine Baltimore, MD, USA
The primary focus of radiochemistry development for positron emission tomography (PET) and single photon emission computed tomography (SPECT) has been dopamine and serotonin neurotransmission. This chapter reviews the PET and SPECT neurochemical brain imaging studies to understand the neurochemical mechanisms underling depression and the response to treatment. It examines the clinical and methodological aspects involved in the design, analysis and interpretation of neurochemical imaging studies. The chapter overviews the studies on neurochemical imaging in depressive illness. While the majority of studies have focused on unipolar depression, the chapter discusses the available data on other depression subtypes. The serotonin and dopamine systems have been the major focus of in-vivo neurochemical imaging studies in depression, as well as other conditions including schizophrenia and anxiety disorders. The chapter also reviews the available neurochemical imaging data for other neurotransmitter systems, and highlights active areas of radiotracer development for other potentially important neurochemical targets.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.